RYAN CARR, M.D., PH.D.
Medical Oncology Physician · ROCHESTER, MN
Individual Active NPI 1366820789
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 513 | 88,505 | $7,992,363 | $2,632,693 | $2,094,564 |
| 2023 | 311 | 31,507 | $3,151,761 | $1,032,585 | $822,545 |
| 2022 | 57 | 109 | $36,975 | $14,672 | $11,774 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 13,204 | $50 | $40 |
| J1453 | Injection, fosaprepitant, 1 mg | 9,000 | $0 | $0 |
| J9267 | Injection, paclitaxel, 1 mg | 6,516 | $0 | $0 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,126 | $48 | $38 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 5,600 | $0 | $0 |
| J9299 | Injection, nivolumab, 1 mg | 5,000 | $31 | $25 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,193 | $0 | $0 |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 1,160 | $5 | $4 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1,030 | $1 | $1 |
| J9041 | Injection, bortezomib, 0.1 mg | 935 | $2 | $1 |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 810 | $21 | $16 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 656 | $0 | $0 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | 60695 | MN |
| Internal Medicine Physician | 207R00000X | 60695 | MN | |
| Hematology & Oncology Physician | 207RH0003X | 60695 | MN |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Minnesota
- NPI 1437278959
- NPI 1003376468
- NPI 1982680583
- NPI 1801877501
- NPI 1437136553
- NPI 1417148180
- NPI 1306879028
- NPI 1265729834
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.